&w=3840&q=100)
ICMR says Indians taking too much salt, launches study to address issue
The scientists have initiated a community-led salt reduction study to address the issue and are focusing on low sodium salt substitutes.
While the World Health Organisation (WHO) recommends less than 5 grams of salt per person per day, studies show that urban Indians consume around 9.2 grams/day, and even in rural areas it is around 5.6 grams/day - both higher than recommended.
One promising tool in this effort is low-sodium salt substitutes -- ?blends where part of the sodium chloride is replaced with potassium or magnesium salts, Dr Sharan Murali, a senior scientist at National Institute of Epidemiology (NIE) and principal investigator of the study, said.
"Lesser sodium consumption helps reduce blood pressure and improves overall heart health, making low-sodium alternatives a meaningful switch, especially for those with hypertension," Dr Murali stated.
"Just switching to low-sodium salt can lower blood pressure by 7/4 mmHg on average'?a small change with a big impact," Dr Murali said.
To tackle the issue of high salt consumption, the NIE has launched a three-year intervention project in Punjab and Telangana, supported by the Indian Council of Medical Research (ICMR).
The goal is to evaluate the effectiveness of structured salt reduction counselling, delivered by health workers at Health and Wellness Centres (HWCs), in reducing blood pressure and sodium intake among individuals with hypertension, senior scientist at NIE, Dr Ganesh Kumar, who is also a part of the study, said..
"We are currently in the first year of the project, focused on baseline assessments and field preparations," Dr Kumar said.
"Counselling materials are not yet finalised; rather, we aim to co-create the intervention package with the community health workers, drawing on their experiences and incorporating their suggestions. It's not just about delivering health education - ?it's about listening, understanding, and building together," Dr Murali said.
To ensure interventions are grounded in reality, the NIE conducted a market survey across 300 retail outlets in Chennai to assess the availability and pricing of low-sodium salt (LSS).
They found that LSS was available in only 28 per cent of retail outlets. It was seen in 52 per cent of supermarkets, but a dismal 4 per cent in small grocery shops.
The price of LSS averaged Rs 5.6 per 100g, more than twice the price of normal iodised salt (Rs 2.7 per 100g).
These findings highlight a critical supply-demand disconnect, Dr Murali said.
"The lower demand for low sodium salt might be leading to its lower availability - it's a proxy indicator of awareness and access," noted Dr. Murali.
To spark a public conversation around salt reduction, the NIE has also recently launched the #PinchForAChange campaign on Twitter and LinkedIn through ICMR-NIE.
Using infographics, facts, and simple messages, the campaign aims to raise awareness about hidden salt sources, promote low-sodium alternatives, and empower individuals to make heart-healthy choices.
"If successful, this project could lead to the integration of sustainable dietary counselling models into the existing public health system. It can bridge the gap between knowledge and action, improve health literacy, and ultimately reduce the burden of hypertension-related diseases.
"This is not just about reducing salt. It's about restoring balance in our diets, our systems, and our hearts. Together, one pinch at a time, we can create lasting change," Dr Murali added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
an hour ago
- Economic Times
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi
Synopsis Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, leading to the dismissal of pending litigation in the US. Incyte has granted Sun a non-exclusive license for oral deuruxolitinib for specific non-oncology indications, including alopecia areata, in the US. Reuters Sun pharma logo( File photo) Sun Pharmaceutical Industries on Monday said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for severe hair the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation, the Mumbai-based drug major said in a statement. As a part of the agreement, Incyte has granted to Sun a limited, non-exclusive license to US Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications, including alopecia areata, in the US, it added. Sun will pay Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license, it stated. Other specific terms of the settlement and license agreement are confidential, it added. In a separate statement, the drug firm announced the launch of Leqselvi (8 mg) tablets in the US medication (deuruxolitinib) is indicated for the treatment of adults with severe alopecia areata."The launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," Richard Ascroft, CEO of Sun Pharma North America, said."As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," he added. Shares of Sun Pharma ended 0.54 per cent higher at Rs 1,681.45 apiece on the BSE.


Time of India
an hour ago
- Time of India
Four years on, home guard's family gets Rs 25 lakh Covid relief in Gujarat
Ahmedabad: Four years after a home guard died during the Covid-19 pandemic, the state govt gave Rs 25 lakh compensation to his widow. The payment was made after the family approached the Gujarat high court, questioning the grounds on which the compensation was denied. The govt had refused to pay the compensation, claiming that the RTPCR/Rapid test result did not disclose that the home guard was suffering from coronavirus. In this case, Mahendrasinh Bhati fell ill when he was deployed for duty in the Krushnanagar police station area in April 2021, during the second wave of the pandemic. His HRCT/CT scan report indicated that he contracted Covid-19, and he was admitted to the Civil Hospital. He died on April 11, 2021, after three days of treatment. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad When his family claimed compensation citing circulars issued by the state govt on March 31, 2020, and July 28, 2020, by which the govt announced Rs 25 lakh ex gratia for the govt employees who perished to Covid infection while performing their duty, the state govt rejected the family's claim. They stated that there was no RTPCR test result reflecting Bhati was suffering from Covid-19, and therefore the family was not entitled to compensation meant for the corona warrior's death. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo Bhati's widow, Sneha, approached the HC through advocate Ratna Vora, demanding the compensation. She questioned the grounds on which the claim was rejected. On June 26, the district commandant of Home Guards issued a communication accepting that Bhati died due to Covid-19 while performing his duty to maintain law and order, and the compensation was paid to his family from the Chief Minister's Relief Fund. Following the payment, the petition became infructuous, and the HC disposed of it.


Time of India
2 hours ago
- Time of India
Maharashtra govt plans tripartite funding to aid needy patients
Mumbai: The state govt is initiating a three-way funding arrangement to improve healthcare access for underprivileged patients. The chief minister's medical assistance cell is currently negotiating with corporate entities and hospitals to establish this tripartite funding structure. Tired of too many ads? go ad free now "A portion of the patient's medical bill will be paid by a corporate house, and the state will also contribute a bit," said Rameshwar Naik, who heads the Chief Minister's Medical Assistance Cell. The third partner would be the treating hospital itself. "We are trying to assess how much hospitals can contribute by reducing charges or providing free services," he added. The tripartite method would ensure more patients get help. "Instead of one corporate house helping one patient, the tripartite method will ensure more patients can be assisted," said a govt official. "The chief minister has also directed that we start crowdfunding efforts for patients who need specialised treatment that runs into lakhs or crores of rupees," said Naik, who heads the state's Charity Hospital Relief Cell. A few months back, Chief Minister Devendra Fadnavis linked the work of his medical assistance cell with the charity commissioner's office to ensure that economically needy patients get access to free beds and care in the various trust-run hospitals in the state. As charity trusts get concessions from the state, their hospitals have to provide 10% of the beds free of cost to families earning less than Rs 1.8 lakh per annum; another 10% of the beds are given at a subsidised rate to families earning less than Rs 3.6 lakh per annum. In the first six months of the year, 23,269 people were provided with Rs 149 crore in assistance by the Chief Minister's Medical Assistance Fund and Charity Hospital Relief Cell. The state is the first to receive Foreign Contribution (Regulation) Act (FCRA) registration to the Chief Minister's Relief Fund of Maharashtra, enabling it to receive foreign donations for "social" programmes.